PreciseDx has shared an update. The company reported that its Chief Scientific Officer and Co-Founder, Gerardo Fernandez, and its VP of AI & Technology, Vijay Yadav, were featured speakers at the Healthcare, AI and Cancer: India–US Partnership Summit 2025, hosted in partnership with Mount Sinai. Their sessions focused on the role of digital pathology and artificial intelligence in cancer diagnostics and treatment, and highlighted PreciseDx’s OncoIntelligence AI platform, which is being positioned to support decision-making and broaden access to advanced breast cancer care technologies globally.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
For investors, this visibility at an international summit and association with Mount Sinai reinforce PreciseDx’s credibility in the AI-enabled oncology diagnostics space. Participation in a forum centered on India–US collaboration also suggests potential opportunities for geographic expansion, partnerships, and clinical adoption in high-growth markets. While the LinkedIn post does not disclose commercial agreements, revenue figures, or regulatory milestones, it indicates ongoing efforts to position OncoIntelligence as a differentiating technology in digital pathology. If the company can translate this scientific and industry recognition into formal collaborations, clinical integrations, and reimbursement pathways, it could strengthen its competitive position and support future revenue growth in the AI-driven cancer diagnostics segment.